CardioExchange Archive

Prostate Cancer and Endocrine Therapy Linked to Increased Risk of Thromboembolic Disease: To assess the risk of thromboembolic disease in men with prostate cancer, Mieke Van Hemelrijck and colleagues analyzed data from the National Prostate Cancer Register in Sweden. They report, in a paper published online in Lancet Oncology, that men with prostate cancer had an elevated risk of thromboembolic disease. The highest risk was observed in those patients receiving endocrine therapy. In an accompanying comment, Phillip Saylor and Annemarie Fogerty conclude that “the data should increase clinical suspicion for venous thromboembolism in men with prostate cancer, and stimulate further study of the potential interactions between androgen deprivation and blood coagulation.”